AMRI has inked a deal with Slovakia’s Saneca Pharmaceuticals to bolster its opium-derived API portfolio.
Bristol-Myers Squibb has acquired the rights to buy immunotherapy firm Promedior and could pay up to $1.25bn (€1.1bn) depending on the clinical development of its lead fibrosis product PRM-151.
Fareva has bought an API plant in France from Merck & Co. and outlined plans to turn it into a high-potency actives site.
Army training is good for a biopharma career according to the US National Center for Therapeutics Manufacturing, which is seeking former military personnel interested in learning about bioprocessing.
Nitroglycerin could make cancer drugs more effective say researchers trying to use the dynamite ingredient to help destroy tumours.